Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | DCLRE1A | Q6PJP8 | 1/20 | 0.35 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19801626 | 1.00 | BAZ2B (0.39) | BAZ2BBAZ2AFFAR1FFAR4PTGER4 | |
| SCHEMBL19804432 | 0.94 | FFAR1 (0.39) | BAZ2BBAZ2AFFAR1FFAR4PTGER4 | |
| SCHEMBL19804774 | 0.92 | PTGS1 (0.40) | FFAR1FFAR4PTGS1BACE1 | |
| SCHEMBL19804659 | 0.92 | PTGS1 (0.40) | FFAR1FFAR4PTGS1BACE1 | |
| SCHEMBL19804668 | 0.91 | FFAR1 (0.42) | FFAR1FFAR4PTGER4EGFRPTGER3 | |
| SCHEMBL19801627 | 0.90 | FFAR4 (0.41) | BAZ2BBAZ2AFFAR1FFAR4PTGER4 | |
| SCHEMBL19804690 | 0.89 | FFAR1 (0.42) | BAZ2BBAZ2AFFAR1FFAR4BACE1 | |
| SCHEMBL19804528 | 0.89 | PTGS1 (0.38) | FFAR1FFAR4EGFRPTGS1BACE1 | |
| SCHEMBL19804610 | 0.89 | FFAR4 (0.40) | FFAR1FFAR4 | |
| SCHEMBL19804683 | 0.89 | FFAR4 (0.40) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | BAZ2B 1586/4885BAZ2A 1968/4885FFAR1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.